thalidomide has been researched along with Erdheim-Chester Disease in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Erdheim-Chester Disease: A rare form of non-Langerhans-cell histiocytosis (HISTIOCYTOSIS, NON-LANGERHANS-CELL) with onset in middle age. The systemic disease is characterized by infiltration of lipid-laden macrophages, multinucleated giant cells, an inflammatory infiltrate of lymphocytes and histiocytes in the bone marrow, and a generalized sclerosis of the long bones.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease." | 8.88 | [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| "Treatment with 2-chlorodeoxyadenosine-based regimen provided partial remission of Erdheim-Chester disease lesions in the brain, while treatment with lenalidomide resulted in complete remission of these lesions." | 7.77 | [Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide]. ( Adam, Z; Cervinek, L; Hájek, R; Hermanová, M; Koukalová, R; Král, Z; Krejcí, M; Kren, L; Mayer, J; Mechl, M; Moulis, M; Pour, L; Prásek, J; Rehák, Z; Sprláková, A; Szturz, P; Zahradová, L, 2011) |
| "We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease." | 4.88 | [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| "Treatment with 2-chlorodeoxyadenosine-based regimen provided partial remission of Erdheim-Chester disease lesions in the brain, while treatment with lenalidomide resulted in complete remission of these lesions." | 3.77 | [Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide]. ( Adam, Z; Cervinek, L; Hájek, R; Hermanová, M; Koukalová, R; Král, Z; Krejcí, M; Kren, L; Mayer, J; Mechl, M; Moulis, M; Pour, L; Prásek, J; Rehák, Z; Sprláková, A; Szturz, P; Zahradová, L, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adam, Z | 2 |
| Sprláková, A | 1 |
| Rehák, Z | 2 |
| Koukalová, R | 2 |
| Szturz, P | 2 |
| Krejcí, M | 2 |
| Pour, L | 2 |
| Zahradová, L | 2 |
| Cervinek, L | 1 |
| Kren, L | 1 |
| Moulis, M | 1 |
| Hermanová, M | 1 |
| Mechl, M | 1 |
| Prásek, J | 1 |
| Hájek, R | 2 |
| Král, Z | 2 |
| Mayer, J | 2 |
| Nebeský, T | 1 |
1 review available for thalidomide and Erdheim-Chester Disease
| Article | Year |
|---|---|
[The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis].
Topics: Aged; Castleman Disease; Erdheim-Chester Disease; Female; Histiocytosis, Langerhans-Cell; Humans; Le | 2012 |
1 other study available for thalidomide and Erdheim-Chester Disease
| Article | Year |
|---|---|
[Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide].
Topics: Adult; Bone Marrow; Brain; Cladribine; Erdheim-Chester Disease; Humans; Lenalidomide; Magnetic Reson | 2011 |